Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk has said plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio...
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating 20th anniversary of FDA's approval of Botox Cosmetic.
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a joint work plan until 2023....
Sanofi has launched its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors....
Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. Virtual…
No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm…
– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million…
Figure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for…
Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company…
Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can…
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients with hemophilia…
– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing myeloablative conditioning as seen…
New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® (luspatercept-aamt)…
SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9,…
